Eli Lilly and Company (NYSE:LLY) Receives Consensus Rating of “Buy” from Brokerages

Eli Lilly and Company (NYSE:LLY) has been given a consensus recommendation of “Buy” by the eighteen research firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, fifteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $258.22.

LLY has been the topic of several research analyst reports. DZ Bank raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $288.00 target price on the stock in a research report on Thursday, August 5th. Citigroup upgraded Eli Lilly and from a “neutral” rating to a “buy” rating and lifted their target price for the company from $210.00 to $265.00 in a research note on Wednesday, September 29th. They noted that the move was a valuation call. Cowen lifted their target price on Eli Lilly and from $250.00 to $300.00 and gave the company an “outperform” rating in a research note on Monday, August 30th. JPMorgan Chase & Co. restated a “buy” rating and issued a $300.00 price target on shares of Eli Lilly and in a research note on Friday, September 24th. Finally, Argus lifted their price objective on Eli Lilly and from $225.00 to $300.00 and gave the stock a “buy” rating in a report on Monday, August 9th.

NYSE LLY opened at $237.87 on Thursday. The stock has a fifty day simple moving average of $247.65 and a 200-day simple moving average of $223.58. Eli Lilly and has a twelve month low of $129.21 and a twelve month high of $275.87. The stock has a market cap of $228.12 billion, a PE ratio of 35.45, a P/E/G ratio of 1.86 and a beta of 0.25. The company has a current ratio of 1.15, a quick ratio of 0.89 and a debt-to-equity ratio of 2.21.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Monday, August 2nd. The company reported $1.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.89 by ($0.02). The company had revenue of $6.74 billion during the quarter, compared to analyst estimates of $6.59 billion. Eli Lilly and had a net margin of 22.71% and a return on equity of 119.12%. Eli Lilly and’s revenue for the quarter was up 22.6% on a year-over-year basis. During the same period in the prior year, the business earned $1.89 EPS. Research analysts predict that Eli Lilly and will post 7.87 EPS for the current year.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 236,542 shares of the stock in a transaction on Tuesday, August 3rd. The stock was sold at an average price of $256.12, for a total transaction of $60,583,137.04. Following the completion of the transaction, the insider now directly owns 108,537,712 shares of the company’s stock, valued at approximately $27,798,678,797.44. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders sold a total of 492,615 shares of company stock valued at $128,197,709 over the last three months. Corporate insiders own 0.13% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in LLY. Zacks Investment Management boosted its position in shares of Eli Lilly and by 2.2% during the 2nd quarter. Zacks Investment Management now owns 1,789 shares of the company’s stock worth $411,000 after acquiring an additional 39 shares in the last quarter. Knowledge Leaders Capital LLC lifted its stake in Eli Lilly and by 1.2% in the 2nd quarter. Knowledge Leaders Capital LLC now owns 3,320 shares of the company’s stock valued at $762,000 after purchasing an additional 40 shares during the last quarter. First Heartland Consultants Inc. raised its stake in shares of Eli Lilly and by 0.9% during the second quarter. First Heartland Consultants Inc. now owns 4,837 shares of the company’s stock valued at $1,110,000 after acquiring an additional 41 shares during the last quarter. Baker Avenue Asset Management LP raised its stake in shares of Eli Lilly and by 3.6% during the second quarter. Baker Avenue Asset Management LP now owns 1,176 shares of the company’s stock valued at $269,000 after acquiring an additional 41 shares during the last quarter. Finally, Sage Rhino Capital LLC raised its stake in shares of Eli Lilly and by 2.1% during the second quarter. Sage Rhino Capital LLC now owns 2,087 shares of the company’s stock valued at $479,000 after acquiring an additional 42 shares during the last quarter. 81.65% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Profile

Eli Lilly & Co engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm’s products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity.

Further Reading: How does the Federal Reserve determine interest rates?

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.